IPL344

DRUG2 trials

Sponsors

Immunity Pharma Ltd.

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)

Phase 1

A Study of IPL344 in the Treatment of ALS Patients

SuspendedNCT03652805

Immunity Pharma Ltd.Amyotrophic Lateral Sclerosis

Start: 2018-08-01End: 2026-02-28Target: 15Updated: 2025-01-10

Phase 2

A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV

SuspendedNCT03755167

Immunity Pharma Ltd.Amyotrophic Lateral Sclerosis (ALS)

Start: 2018-12-09End: 2027-02-28Target: 15Updated: 2025-01-10